Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 8 Neoplasms 6 Triple Negative Breast Neoplasms 4 Lung Neoplasms 4 Endometrial Neoplasms 4 Ovarian Neoplasms 3 Neoplasm Metastasis 3 Breast Neoplasms 3 Small Cell Lung Carcinoma 2 Melanoma 2 Carcinosarcoma 2 Bile Duct Neoplasms 2 Advanced Solid Tumours 2 Uterine Cervical Neoplasms 1 Thoracic Neoplasms 1 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Solid Tumour Refractory to Conventional Treatment 1 Salivary Gland Neoplasms 1 SCLC 1 Respiratory Tract Neoplasms 1 Respiratory Tract Diseases 1 Prostatic Neoplasms 1 Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma 1 Pancreatic Neoplasms 1 Osteosarcoma 1 Non Small Cell Lung Cancer NSCLC 1 Neoplasms by Site 1 Myelodysplastic Syndromes 1 Lymphoma, Non-Hodgkin 1

Interventions

durvalumab 2 tremelimumab 1 ceralasertib 1 aflutinib 1 Radiotherapy 1 Pemetrexed 1 Gemcitabine 1 Cisplatin 1 Carboplatin 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Non Small Cell Lung Cancer NSCLC × ceralasertib × Clear all

NCT06680050 2025-12-18

AUSTRAL

Mario Negri Institute for Pharmacological Research

Phase 2 Recruiting

Non Small Cell Lung Cancer NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡